Laser Therapy Shows Promise for Drug-Resistant Epilepsy Treatment

Drug-resistant epilepsy affects millions worldwide, with mesial temporal lobe epilepsy (MTLE) being the most common form requiring surgical intervention. Traditional treatment involves open brain surgery to remove seizure-generating tissue, but this carries significant risks and requires lengthy recovery periods.

This landmark study analyzed outcomes from the LAANTERN registry, tracking 145 patients across 15 major epilepsy centers who underwent laser interstitial thermal therapy (LITT) for drug-resistant MTLE. LITT uses precisely targeted laser energy to ablate seizure-generating brain tissue through a minimally invasive approach.

The results were encouraging: 58% of patients achieved complete seizure freedom at 2 years, with 57% meeting international epilepsy outcome standards. Importantly, the procedure was remarkably well-tolerated, with patients averaging just 1-day hospital stays and minimal pain scores. Only 16.5% experienced adverse events, most being mild and temporary. One-third of patients were able to reduce or eliminate their anti-seizure medications.

Quality of life improvements were substantial and sustained across nearly all measured timepoints. The procedure worked equally well in pediatric patients, suggesting broad applicability across age groups. Notably, no specific patient characteristics predicted better outcomes, indicating the treatment may benefit diverse patient populations.

These findings represent a significant advance in epilepsy treatment, offering patients a safer alternative to traditional surgery with comparable effectiveness. The minimally invasive nature addresses patient preferences for less risky procedures while maintaining therapeutic benefit.